Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20943042 | 0.95 | FGFR1 (0.53) | FGFR1FGFR4MAPK3EGFRFGFR2 | |
| SCHEMBL20943045 | 0.93 | EGFR (0.56) | FGFR1FGFR4MAPK3EGFRSRC | |
| SCHEMBL20943007 | 0.93 | FGFR4 (0.55) | FGFR1FGFR4MAPK3EGFRFGFR2 | |
| SCHEMBL20943064 | 0.91 | FGFR1 (0.57) | FGFR1FGFR4MAPK3EGFRFGFR2 | |
| SCHEMBL21019625 | 0.91 | FGFR1 (0.53) | FGFR1FGFR4MAPK3EGFRFGFR2 | |
| SCHEMBL20943059 | 0.91 | FGFR4 (0.53) | FGFR1FGFR4MAPK3EGFRFGFR2 | |
| SCHEMBL20943029 | 0.90 | FGFR4 (0.65) | FGFR1FGFR4MAPK3EGFRFGFR2 | |
| SCHEMBL20943022 | 0.90 | EGFR (0.56) | FGFR1FGFR4MAPK3EGFRFGFR2 | |
| SCHEMBL20943039 | 0.90 | FGFR4 (0.54) | FGFR1FGFR4MAPK3EGFRFGFR2 | |
| SCHEMBL20943027 | 0.89 | FGFR1 (0.51) | FGFR1FGFR4MAPK3EGFRFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696675-B2 | Imidazopyridopyrimidine derivative compound and use thereof | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | claimed |
| US-20190152973-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | claimed |
| EP-3476846-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2019-05-01 | — | — | EP | claimed |
| US-10696675-B2 | Imidazopyridopyrimidine derivative compound and use thereof | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20190152973-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | disclosed |
| EP-3476846-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2019-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696675-B2 | Imidazopyridopyrimidine derivative compound and use thereof | FGFR1, FGFR4, FGFR3 | FGFR1 1/4885FGFR4 2/4885MAPK3 1078/4885 |
| US-20190152973-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885FGFR4 4/4885MAPK3 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.